Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1381-1400 of 1,743 trials

HER2-Expressing Cancers: VIR-5818 and Pembrolizumab Study

We are testing a new treatment combining VIR-5818 with Pembrolizumab for patients with advanced or metastatic HER2-expressing cancers. This study aims to evaluate the safety and effects of this combination.

HER2-Positive Cancers>2 yearsSafety phase (I)Oncology

RR001 Gene Therapy for Locally Advanced Pancreatic Cancer

We are studying a new gene therapy combined with chemotherapy to see if it is safe and effective for patients with locally advanced pancreatic cancer. The trial will help determine the best dose and how well this treatment works.

Pancreatic CancerLocally Advanced Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: Eftilagimod Alpha Treatment

We are exploring a new treatment using eftilagimod alpha for patients with advanced solid tumors. The study looks at its safety and how it works with other therapies.

Non-Small Cell Lung Cancer (NSCLC)Urothelial CarcinomaMalignant Solid Tumor>2 yearsSafety phase (I)Oncology

Ifinatamab Deruxtecan for Metastatic Prostate Cancer

We are studying ifinatamab deruxtecan to see if it is safe and effective for men with metastatic castration-resistant prostate cancer. This trial will help us understand how well it works compared to other treatments.

Metastatic Castrate Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib for patients with Chronic Myeloid Leukemia who have the T315I mutation and have not responded to ponatinib. The trial aims to see how well it works and how safe it is.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Kamada-AAT for Inhalation in Alpha-1 Antitrypsin Deficiency

We are studying a new inhalation treatment for adults with congenital Alpha-1 Antitrypsin Deficiency to see if it improves lung function compared to a placebo. The trial also looks at safety and immune responses to the treatment.

Congenital Alpha-1 Antitrypsin Deficiency>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Severe Influenza: Early Oseltamivir Carboxylate Levels

We are studying how low levels of oseltamivir carboxylate in critically ill patients with severe influenza affect their recovery and survival. This research may help improve treatment for patients in intensive care.

Severe Influenza Infection>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Anesthesia in Newborns: Propofol vs. Thiopental

We are studying the right doses of propofol and thiopental for safely inducing anesthesia in newborns. The trial also examines how these drugs affect breathing and heart function.

Neonates Undergoing General Anesthesia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Prostate Cancer Imaging: 99mTc-MIP-1404 SPECT/CT Study

We are comparing a new imaging technique to standard methods for detecting prostate cancer spread in patients. This study aims to see if the new method improves detection of lymph node and bone metastases.

Prostate Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesOtolaryngologyUrology

Pulmonary Tuberculosis: Cysteamine Therapy Study

We are investigating the safety of cysteamine as an additional treatment for adults with pulmonary tuberculosis. This study aims to see how it affects bacterial load and immune response during standard TB therapy.

Pulmonary Tuberculosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

CAR T Cell Therapy for Acute Leukemia in Young Patients

We are studying a new treatment using donor-derived CAR T cells for children and young adults with recurrent acute leukemia. The trial aims to assess the safety and effectiveness of this therapy after previous stem cell transplantation.

Recurrent Acute Lymphocytic Leukaemia>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology

GRAALL2014: Clinical Trial Study

We are investigating a new treatment approach for a specific health condition. This trial aims to understand its effects and potential benefits for participants.

Acute Lymphoblastic Leukemia (ALL)>2 yearsEfficacy phase (II)Internal Medicine

Hematologic Malignancies: HTLP Injection Study

We are testing a new injection to help adults with blood cancers recover their immune system after umbilical cord blood transplantation. This study aims to see if it is safe and effective for improving recovery.

Acute Myeloid Leukemia (AML)>2 yearsSafety phase (I)Hematology

Ruxolitinib for Children with Hemophagocytic Lymphohistiocytosis

We are studying whether Ruxolitinib, combined with corticosteroids, can improve survival in children with HLH until they receive a stem cell transplant. The trial will also look at how well the treatment works and any side effects.

Haemophagocytic Lymphohistiocytosis in Children>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Oropharyngeal Cancer: Comparing Treatment Options

We are studying different treatment regimens for patients with intermediate and high-risk oropharyngeal cancer to see if they improve survival and quality of life. This trial also aims to evaluate side effects and the cost-effectiveness of these treatments.

Oropharyngeal Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncology

High-Risk Polycythemia Vera: Ruxolitinib vs. Standard Therapy

We are comparing a new medication, ruxolitinib, with standard treatments for high-risk polycythemia vera patients. The goal is to see which option better prevents serious complications and improves quality of life.

Polycythemia Vera>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Cancer Imaging: New Non-Invasive Technique

We are exploring a new imaging method that combines two techniques to study how cancer cells and healthy tissues use energy. This may help improve cancer diagnosis and treatment strategies.

Pancreatic Neuroendocrine TumorNeuroendocrine CarcinomaSoft Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementAllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryPulmonologyRheumatologyUrology

HIV-1 Infection: ART with Long-Acting Antibodies

We are studying whether adding long-acting HIV-specific antibodies to standard treatment can help people with primary HIV-1 infection achieve better control after stopping therapy. This trial will also look at how well participants tolerate the treatment.

HIV-1 Infection>2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesPartially RemoteInfectious Diseases

Immunotherapy for Cutaneous Squamous Cell Carcinoma

We are studying whether immunotherapy can help patients with skin cancer achieve remission without surgery or radiation. This trial aims to assess the treatment's effectiveness and safety over time.

Skin Cancer (Cutaneous Squamous Cell Carcinoma)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology

Advanced Breast Cancer: Inavolisib Treatment Study

We are studying a new treatment combining inavolisib with standard medications for patients with advanced hormone receptor-positive breast cancer. The goal is to see if this combination works better than a placebo in managing the disease.

Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology